DGAP-News: 4SC Full Year Results - Conference Call and Webcast, 29 March, 2011
(firmenpresse) - DGAP-News: 4SC AG / Key word(s): Final Results
4SC Full Year Results - Conference Call and Webcast, 29 March, 2011
22.03.2011 / 07:30
---------------------------------------------------------------------
Planegg-Martinsried, Germany, 22 March, 2011 - 4SC AG (Frankfurt, Prime
Standard: VSC) a drug discovery and development company, will announce its
results for the financial year 2010 (ended 31 December, 2010) on 29 March,
2011. The senior management team will host a conference call at 3pm CET
(9am EST) on the day to inform about the results for the quarter and all
important developments in the reporting period.
Access to the presentation slides can be obtained at:
http://4sc290311-live.cyber-presentation.de
Participants can access the conference under the following data:
Date: 29 March, 2011
Time: 3pm CET (9am EST)
Dial-in numbers:
0800 10 12 072 (Germany)
0800-358-0886 (UK)
1-877-941-6012 (USA)
+49 (0) 6103 485 3001 (other countries)
Conference ID: 4421825
Approximately two hours after the live presentation, an audio replay of the
conference will be available on the 'investors' section of the homepage
www.4sc.com.
For further information please contact:
Yvonne Alexander
4SC AG
Investor&Public Relations
Tel.: +49 (0) 89 70 07 63 - 0
yvonne.alexander(at)4sc.com
About 4SC
4SC AG (ISIN DE0005753818) is a drug discovery and development company
focused on autoimmune and cancer indications. Vidofludimus (4SC-101), a
small molecule, is currently in a Phase IIb study in rheumatoid arthritis
and has completed a Phase IIa exploratory study in inflammatory bowel
disease. The company's lead oncology compound, resminostat (4SC-201), a pan
histone deacetylase (HDAC) inhibitor, is in Phase II trials in
hepatocellular carcinoma and Hodgkin's lymphoma. Two further oncology
compounds, 4SC-203 and 4SC-205 are in Phase I studies. 4SC develops drug
candidates until proof-of-concept in order to generate value creating
partnerships with the pharmaceutical industry in return for advance and
milestone payments as well as royalties.
Founded in 1997, 4SC has 94 employees and has been listed on the Prime
Standard of the Frankfurt Stock Exchange since December 2005.
For further information please visit www.4sc.com.
End of Corporate News
---------------------------------------------------------------------
22.03.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Deutschland
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public(at)4sc.com
Internet: www.4sc.de
ISIN: DE0005753818WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
116287 22.03.2011
Datum: 22.03.2011 - 07:30 Uhr
Sprache: Deutsch
News-ID 33526
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 219 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: 4SC Full Year Results - Conference Call and Webcast, 29 March, 2011"
steht unter der journalistisch-redaktionellen Verantwortung von
4SC AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
